Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy targets Hard-to-Treat prostate cancer

NCT ID NCT04946370

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 32 times

Summary

This study tests whether adding a targeted radiation drug (225Ac-J591) to standard immunotherapy (pembrolizumab) and hormone therapy works better for men with advanced prostate cancer that has spread and stopped responding to treatment. About 52 men will participate. The goal is to see if the combination shrinks tumors, lowers PSA levels, and improves survival, while monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Columbia University Irving Cancer Center

    RECRUITING

    New York, New York, 10032, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

  • New York Presbyterian/Brooklyn Methodist Hospital

    RECRUITING

    Brooklyn, New York, 11215, United States

    Contact

  • New York Presbyterian/Weill Cornell Medical Center

    RECRUITING

    New York, New York, 10021, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.